Navigation Links
Targeted blocking of cell death prevents fatal condition septic shock
Date:12/27/2011

Ghent, Belgium 27 December 2011 - Researchers of VIB and UGent have discovered a new approach to preventing septic shock, an often fatal extreme inflammatory reaction of the body. It is the most frequent cause of death at intensive care departments in hospitals. In sepsis, acute inflammation is attended by low blood pressure and blood clots, causing the organs to stop working. Only recently, the Brazilian football legend Socrates, died of the consequences of this condition. In a new study in the top journal Immunity, Peter Vandenabeele and colleagues of VIB-UGent described how blocking a particular form of cell death (necroptosis) fully protects mice against this fatal inflammation.

"This research opens up new perspectives for the treatment of fatal inflammatory diseases such as sepsis," says researcher Peter Vandenabeele of VIB and UGent. "By blocking necroptosis, we have found a possibly new target for a therapy."

Sepsis and SIRS

The Ghent scientists studied the Systemic Inflammatory Response Syndrome (SIRS). This is a severe inflammatory reaction affecting the entire body. It may be caused by an infection, such as sepsis, or by physical injury such as severe burns or a serious road accident.

Role of TNF in SIRS

The cytokine tumor necrosis factor (TNF) plays a crucial role in the occurrence of SIRS. The presence of TNF may trigger the cells to cause inflammation and programmed cell death. Inflammation is a necessary response in the body generated, among other things, to prevent or restore damage when injury and infections have been sustained. Programmed cell death can occur in two ways: via apoptosis or via necroptosis. The difference between the two forms of cell death lies among other things in communication with our immune system. Necroptosis usually provokes a strong reaction by the immune system whereas apoptosis proceeds unnoticed.

RIPK: potential therapeutic target for treatment of SIRS and sepsis

Peter Vandenabeele and his colleagues Linde Duprez, Nozomi Takahashi and Anje Cauwels have discovered that in mice eliminating apoptosis did not have any impact on lethal SIRS whereas eliminating nepcroptosis afforded full protection against the condition. The scientists managed to block nepcroptosis by eliminating RIPK (Receptor-interacting serine/threonine-protein kinase) molecules. The experiments showed that RIPK plays a crucial role in SIRS and sepsis. The molecule appears to constitute a potential therapeutic target for the treatment of SIRS and sepsis. Further research should clarify the potential applications of this discovery.


'/>"/>

Contact: Joris Gansemans
joris.gansemans@vib.be
VIB (the Flanders Institute for Biotechnology)
Source:Eurekalert

Related biology news :

1. Targeted antibacterial proteins may offer antibiotic alternative
2. GNS Healthcare Collaborates with NCI in New Approach to Lung Cancer; Supercomputer Analysis to Aid in Matching Targeted Drugs to Patients
3. GNS Healthcare Collaborates with NCI in New Approach to Lung Cancer; Supercomputer Analysis to Aid in Matching Targeted Drugs to Patients
4. Targeted adalimumab treatment can optimize long-term outcomes for patients with early RA
5. Lesser-known Escherichia coli types targeted in food safety research
6. Delivering drugs to the brain: New research into targeted treatment of Alzheimers
7. New targeted therapy adds benefit to erlotinib in some patients with advanced lung cancer
8. New mechanisms of tumor resistance to targeted therapy in lung cancer are discovered
9. UC to test targeted treatment for prostate cancer
10. Caltech-led team provides proof in humans of RNA interference using targeted nanoparticles
11. New subtype of breast cancer responds to targeted drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/4/2017)... , Jan. 4, 2017  For the thousands of attendees at ... global leader in connected health and biometric measurement devices and services, will ... On display in A&D Medical,s special CES Exhibit Suite ... the ongoing expansion of the company,s WellnessConnected product platform.  ... ...
(Date:12/22/2016)... , Dec. 20, 2016  As part of its longstanding ... leading personal genetics company, recently released its latest children,s book, ... The book focuses on the topics of inheritance and variation ... Standards (NGSS) taught in elementary school classrooms in the US. ... series by illustrator Ariana Killoran , whose previous book ...
(Date:12/20/2016)... Dec, 20, 2016   Valencell , the ... and STMicroelectronics (NYSE: STM), a global semiconductor ... applications, announced today the launch of a new, ... wearables that includes ST,s compact SensorTile ... biometric sensor system. Together, SensorTile and Benchmark ...
Breaking Biology News(10 mins):
(Date:1/11/2017)... , ... January 11, 2017 , ... ... are observed in clinical settings, it is becoming increasingly clear that the evolution ... on culture-based methods, the standard in the study of clinical resistance, has vastly ...
(Date:1/11/2017)... ... January 11, 2017 , ... IsoPlexis Corporation ... platform to measure the proteomic function of individual cells in patients, today announced ... grant from the National Institute on Aging of the National Institutes of Health ...
(Date:1/11/2017)... Collins, Colorado (PRWEB) , ... January 11, 2017 ... ... of dynamic aqueous plasma technology platforms, announced today that the National Science Foundation ... IIB supplement for $500,000. The funds will be used to commercialize the Symbios ...
(Date:1/11/2017)... ... January 11, 2017 , ... Advanced Polymer Monitoring Technologies (APMT) ... Bartylla will lead European initiatives for APMT’s product lines serving polymer and biopharmaceutical ... to European manufacturers and researchers. Bernhard brings significant experience in our application areas ...
Breaking Biology Technology: